

Technology Advisory Committee A Interests Register

Ibrutinib for treating Waldenstrom's macroglobulinaemia [ID3778] (CDF review of TA491)

Publication Date: 8 June 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Dima El-Sharkawi	Clinical expert	Direct & Indirect financial	<p>Dr El-Sharkawi has received money from Janssen for advisory boards and honoraria for talks</p> <p>Her institution received research funding from Pfizer and Roche, and she received travel support to attend ESMO 2019 from Leo Pharmaceuticals. Received speaker's fees from Pfizer, Lilly and AstraZeneca, and registration for ASCO 2021 and ESMO 2021 was received from Lilly.</p>	N/A	August 2021	N/A	It was agreed her declarations would not prevent Dr El-Sharkawi from providing expert advice to the committee
Dr Shirley D'Sa	Clinical expert	Direct and Indirect financial	Dr D'Sa's research fund has received grants from Janssen, she has worked on projects with Janssen to collect and analyse data from the RMR.	N/A	August 2021	N/A	It was agreed her declarations would not prevent Dr D'Sa from providing expert

			<p>She has received grant funding from BeiGene UK Ltd.</p> <p>She is on the Medical Advisory Board of BeiGene UK Ltd and has received honoraria for this and speakers' fees.</p>				advice to the committee
Dominic Pivonka	Committee member	Direct financial	<p>His employer (AbbVie) acquired the company which developed ibrutinib in 2015 and markets ibrutinib in the United States.</p>	N/A	November 2021	N/A	As a direct conflict Dominic did not participate in discussions on this appraisal.